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C-MPL EXPRESSION IN OSTEOCLAST PROGENITORS: A NOVEL ROLE FOR 
THROMBOPOIETIN IN REGULATING OSTEOCLAST DEVELOPMENT. Calvin L Barnes, Yougen 
Xi, Kimberly M Wilson, Mark C Horowitz, and Melissa A Kacena.  Section of Bone Biology, Department 
of Orthopaedic Surgery and Rehabilitation, Yale University, School of Medicine, New Haven, CT.  
 
A new paradigm has evolved in which multiple regulatory interactions between the skeletal and 
hematopoietic systems have been identified.  Previous studies have demonstrated that megakaryocytes 
(MK) play a dual role in skeletal homeostasis by stimulating osteoblast proliferation and simultaneously 
inhibiting osteoclast (OC) development.  Here we identify a novel regulatory pathway in which the main 
MK growth factor, thrombopoietin (TPO), directly regulates osteoclastogenesis.  To study the role of TPO 
in OC development, spleen or bone marrow (BM) cells (2x106 cells/ml) or BM macrophages (BMM, 1x105 
cells/ml) from C57BL/6 mice , as a source of OC precursors, were cultured with M-CSF (30 ng/ml) and 
RANKL (50 ng/ml) to induce OC formation.  TPO (0.1-1000 ng/ml) and/or primary MK (0-0.5%), derived 
from C57BL/6 fetal livers, were titrated into these cultures and OC were identified as tartrate resistant acid 
phosphatase positive (TRAP+) giant cells with >3 nuclei.  There was a significant, up to 15-fold reduction 
in OC formed when MK were added to all OC generating cultures, p < 0.001.  Moreover, if OC generating 
cultures did not contain MK or MK progenitors, TPO treatment significantly enhanced OC formation up to 
six-fold, p < 0.01.  This data demonstrates that MK are responsible for the inhibition of OC formation and 
that in cultures containing MK or MK progenitors such as BM or spleen cells, that TPO acts indirectly to 
inhibit OC formation by stimulating megakaryopoiesis, whereas in the absence of MK or MK progenitors 
TPO directly enhances OC formation.  This conclusion is further supported by Real-Time PCR data which 
demonstrates that OC progenitors express c-mpl, the TPO receptor, albeit at low levels when compared to 
expression of c-mpl on MK.  Finally, we have begun to dissect the c-mpl signaling pathway in OC 
progenitors.  We have found that TPO induces tyrosine phosphorylation of several specific cellular proteins 
in the JAK/STAT pathway.  Thus, TPO acts in a somewhat paradoxical manner by inhibiting OC formation 
through the stimulation of MK, while simultaneously playing a direct role in enhancing osteoclastogenesis.   
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Bone is a dynamic tissue due to its intimate functional relationship to bone 
marrow (BM).  BM contains osteogenic, hematopoietic, and immune cells.   Other cell 
lineages are also present in BM and are supported by the stromal cell system. The close 
juxtaposition of these cells makes BM the focus for many of the regulatory interactions 
required for homeostatic development of bone. Changes in these regulatory interactions 
may result in altered bone formation or resorption, providing clues as to how skeletal 
homeostasis is maintained.  Bone remodeling is a coupled process of bone resorption 
followed by bone formation.  This is a constant, balanced process and the interruption of 
either bone resorption or formation leads to pathological conditions.  
The mature, multi-nucleated osteoclast (OC) is the cell that resorbs bone.  Early 
studies, using electron microscopy demonstrated the ultrastructure of the actively 
resorbing OC, and revealed distinguishing features.  These consisted of large numbers of 
lysosomes, vacuoles, and a specialized portion of its plasma membrane that lies adjacent 
to bone actively being resorbed, now referred to as the “ruffled border” (1).  This portion 
of the plasma membrane is intricately folded with finger-like extensions into the 
cytoplasm.  Adjacent to the ruffled border is the sealing zone, which is directly apposed 
to the bone and is composed of F- actin and punctuate protrusions of cytoplasm known as 
podosomes that are devoid of organelles (2).  The actin filaments and folds of the ruffled 
border provide the OC with a controlled surface area where hydrogen and proteolytic 
molecules can selectively dissolve bone.   It is now known that when the OC is induced 
to resorb bone, acidic vesicles containing proton pumps are recruited to the ruffled border 
by the actin network (3-6).  These proton pumps (H+ ATPases) secrete hydrogen ions 
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and are accompanied by the concomitant release of chloride ions from chloride channels 
(7).  The net result of this process is creation of an acidic environment with hydrochloric 
acid which demineralizes bone.  Cathepsin K, a lysosomal protease, has been shown to 
degrade the organic bone matrix following demineralization (8, 9).  
 OC are hematopoetic in origin.  Some of the first evidence was discovered using 
parabiosis techniques in which osteopetrotic mice and rats had their circulatory system 
attached to their wild type, normal counterpart and osteoclastic activity was detected in 
the osteopetrotic animals (10-12).  Many recent studies demonstrate that OC are of the 
monocyte/macrophage lineage, although the identity of the earliest OC precursor remains 
elusive.  This ongoing research is outside the scope of this paper.  For a complete review, 
consult Roodman (13).  Currently there are 3 competing models of OC formation.  The 
first model states that the hematopoetic stem cell gives rise to granulocyte-macrophage 
progenitor cell, CFU-GM, and that this cell produces OC.  The second model proposes 
that the hematopoetic stem cell produces CFU-GM, which in turn produces monocytes 
and macrophages, of which some can be induced to form OC.  The third model argues 
that the hematopoetic stem cell produces CFU-GM and CFU-O, a distinct progenitor cell 
which matures and fuses to form OC, and that CFU-GM does not directly produce OC 
(13).   
However, in spite of the controversy concerning the earliest stem cell, it has been 
known for some time that in vitro maturation of macrophages into OC requires marrow 
stromal cells or osteoblasts (OB) (14).  It is now known that OB and marrow stromal 
cells produce macrophage colony stimulating factor (M-CSF) and receptor for activation 
of nuclear factor kappa B ligand (RANKL) and that these two factors are necessary for 
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osteoclastogenesis (15-18).  More recently, it was discovered that OB and stromal cells 
also produce the soluble mediator osteoprotegrin (OPG) which acts as a decoy receptor 
for RANKL, competing with RANK, thus inhibiting OC formation (18, 19).  Fig. 1 is a 
model illustrating the actions of RANKL, M-CSF, and OPG in OC development.     
  
Figure 1.  Model developed by Teitelbaum (42) depicting osteoclastogenesis and bone 
resorption.  OB and stromal cells express RANKL and M-CSF which interact with their 
receptors, RANK and c-fms, respectively, on cells of the monocyte/macrophage lineage, 
initiating OC development.  OPG acts as a decoy by binding RANKL and inhibiting OC 
formation.  The mature OC attaches to the bone matrix and a ruffled membrane and 
sealing zone are created.  This small area of bone matrix contained within the sealing 
zone is the microenvironment where bone resorption takes place.  The acidic 
environment generated by the OC mobilizes the mineral phase of bone and allows for 
organic matrix degradation by cathepsin K.   
 
It is becoming increasingly evident that within the stroma of the marrow, there 
exist a complicated network of paracrine, cell-cell, and cell-matrix interactions that work 
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in concert to regulate the production and activity of OC.  Most notably, TNF-α and IL-1 
have a direct stimulatory effect on OB and marrow stromal cells to produce RANKL and 
M-CSF, thus promoting osteoclastogenesis (20).   Moreover, TNF-α and IL-1 have been 
shown to stimulate the production of adhesion molecules leading to increased cell-cell 
interactions between bone stromal cells and hematopoietic cells (21).  Also, IL-6 and IL-
11 have been shown to stimulate osteoclastic activity (22, 23).  Several other factors are 
known to inhibit osteoclastogenesis.  In addition to OPG, these inhibitory molecules 
include, but are not limited to: interleukin (IL)-4, IL-10, IL-12, IL-13, IL-18, interferon 
gamma (IFN-γ), transforming growth factor beta (TGFβ), granulocyte-macrophage-
colony stimulating factor (GM-CSF), OC inhibitory lectin (OCIL), calcitonin, amylin, 
and calcitonin gene-related peptide (24-38).  Therefore, it is likely that additional 
undiscovered inhibitory cytokines exist.   
 
The Megakaryocyte 
Megakaryocytes (MK) arise from pluripotential, hematopoetic stem cells and pass 
through a series of identifiable stages of differentiation, culminating in terminally 
differentiated MK. The major function of MK is the formation of platelets.  This occurs 
by differentiated MK becoming ploidy through a process termed endomitosis. 
Endomitosis consists of DNA replication and a mitotic event with sister chromatid 
separation, but no cytokinesis (39).  This leads to the formation of the demarcation 
membrane system, an extensive system of membranes within the MK cytoplasm, which 
gives rise to proplatelets.  Proplatelets are the presumed structure between MK and 
platelets that have been observed in vitro and in vivo (40).  Proplatelets are long sinuous 
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processes that extend from the MK and either fragment to form platelets or, alternatively, 
attenuation points form pinching off newly formed functional platelets (41). 
   The molecular dissection of the MK differentiation pathway has been greatly 
facilitated by the identification of transcription factors required for the cells successful 
advance from stage to stage (Fig. 2).  Loss of these specific factors precludes the cells 
from continued maturation, and results in the accumulation of cells at the latest stage of 
differentiation prior to the arrest.  The selective loss of two different transcription factors, 
GATA-1 and NF-E2, which were originally thought to be required exclusively for 
erythroid lineage development, have now been shown to play a critical role in MK 
differentiation.  Knock-down mice in the case of GATA-1, and knock-out mice in the 
case of NF-E2, exhibit a phenotype characterized by a marked megakaryocytosis and 
thrombocytopenia (43, 44).  The thrombocytopenia is a result of the maturational arrest 
of MK differentiation in which GATA-1 halts differentiation at a stage between immature 
and mature MK, where as NF-E2 arrests development at a later stage just prior to 
terminal differentiation (Fig. 2).   
  














FOG FOG GATA-1 NF-E2
maf 
Figure 2.  Schematic illustrating stages of MK differentiation and required transcription factors. 
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Thrombopoietin, C-mpl, and Megakaryocyte Signal Transduction 
The cytokine, thrombopoietin (TPO) is the primary mediator of primitive 
megakaryocytic progenitor survival and proliferation, megakaryopoiesis, MK ploidy, and 
maturation (45-52).  Its’ receptor is the proto-oncogene c-mpl (53).  The role of TPO and 
its receptor c-mpl in thrombopoiesis was elucidated in the early to mid 1990s.  The 
pivotal experiments demonstrated that oligodeoxynucleotides antisense to c-mpl inhibited 
in vitro megakaryocytopoiesis (54).  The role of c-mpl as the TPO receptor was further 
substantiated when it was shown that in murine models deficient in c-mpl, a 
thrombocytopenic phenotype existed (55).  The ligand to c-mpl, TPO, was then purified 
and/or cloned by several research groups, clearly demonstrating its role as the primary 
regulator of thrombopoiesis (50, 51).   
TPO is a 332 amino acid polypeptide containing two recognizable domains.  The 
N-terminal region contains the receptor binding domain and is responsible for the 
biological activity of TPO (46).  The N-terminal region has marked homology to 
erythropoietin (EPO) and its crystal structure has been identified as containing 4-α-
helices arranged in an anti-parallel bundle fold (56, 57).  This structural feature has been 
demonstrated in many cytokines including granulocyte colony-stimulating factor (G-
CSF), GM-CSF, and growth hormone (GH) (58).  The highly glycosylated, C-terminal 
region is thought to be responsible for protein secretion and stability (59).  TPO was 
originally thought to be primarily produced by hepatocytes in the liver and convoluted 
tubular cells in the kidney.  However, in the last decade it has become increasingly clear 
that TPO is also expressed in stromal cells within the BM (60-64).  TPO has been 
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measured in blood in response to thrombocytopenic states caused by both antibody 
mediated and myelosuppressive techniques (65, 66).   
C-mpl is a type I transmembrane protein belonging to the hematopoietic cytokine 
receptor family (67).  Similar to the common beta chain (βc) shared by IL-3, IL-5, and 
GM-CSF, the extracytoplasmic domain of c-mpl consists of duplicate cytokine receptor 
modules (CRM) (68).  The cytoplasmic domain of c-mpl is highly conserved across 
species.  There is 86% homology, at the amino acid level, between mouse and human mpl 
(69).  The human c-mpl gene is composed of 12 exons (70).  There are currently 4 
identified splice variants of c-mpl.  The predominant, full-length protein is referred to as 
the P-form.  In humans, the P-form consists of a transmembrane domain and 122 
cytoplasmic residues.  The K-form diverges from the P-form after the 9th cytoplasmic 
amino acid and terminates within intron 10, this protein does not transduce a proliferative 
signal and has no known biological activity; however, it is possible that mpl-K acts as a 
dominant negative receptor by heterodimerizing with mpl-P following ligand binding 
(71).  The third splice variant, mpl-S, is a secreted form of mpl.  Mpl-S results from 
alternative splicing of exon 8 directly to exon 11.  This eliminates the transmembrane 
domain, the initial cytoplasmic residues, and the juxtamembrane WSXWS motif (70-72).  
The 4th isoform, c-mpl-del, occurs from alternative splicing between exons 8 and 9 (lacks 
72 bp), which results in the internalization of the receptor (73). 
Two motifs in the cytoplasmic domain, box1 and box2, are conserved in the 
hematopoietic cytokine receptor family, and are 100% homologous between mouse and 
human mpl (69).  Box1 appears to be required for signal transduction in all receptors 
examined, while box2 is not necessarily required for proliferative signals (74-78).   
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The signaling domain in c-mpl is 121 amino acids in mice and 122 amino acids in 
humans.  It is immediately downstream of the hydrophobic transmembrane domain which 
is composed of 25 residues.  While the c-mpl signaling domain is 91% homologous 
between mouse and human, it does not share significant homology to other proteins (79).  
The signal transduction of TPO when it binds to c-mpl is very complex and is the 
subject of active research by several investigators. Evolution has seemingly fortified the 
TPO/c-mpl signal transduction mechanism with redundancy to ensure a proliferative  
signal will be transmitted (80).  There is evidence that TPO signals proliferative events in 
target cells through a JAK/STAT pathway.  It was demonstrated that when TPO binds to 
c-mpl, the receptor dimerizes, consequently tyrosine kinases, specifically JAK2 and 
TYK2, activate each other by transphosphorylation (81).  It was later shown that JAK2, 
not TYK2 was required for mediated signaling (82).  TPO is also known to induce 
activation of STAT5 and STAT3 following JAK2 activation (83).  STAT proteins, once 
activated by tyrosine kinases, translocate to the nucleus and activate genes that signal 
cellular growth and division such as cyclin D and p21.   
  TPO has also been shown to signal proliferation in cells with a JAK-STAT 
deletion (84).  This research group demonstrated that TPO mediated phosphorylation of 
Shc, vav, mitogen-activated protein kinase (MAPK) and Raf-1, which then lead to 
induction of c-fos and c-myc.  Moreover, this group also demonstrated that wild-type and 
mutant c-mpl receptors activated phosphatidylinositol (PI) 3-kinase when stimulated with 
TPO and that TPO induced proliferation was suppressed in the presence of a PI 3-kinase 
inhibitor.  It is now evident that the MAPK signaling cascade, Shc, Ras signaling, as well 
as PI 3-kinase, play some role in TPO signal transduction (85-90).  More recently, 
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microarray profiles demonstrated increased kinase activity in Fyn and Lyn in human 
MKs after TPO stimulation, suggesting that Scr family kinases are also involved in TPO 
signal transduction (91).  Protein Kinase C (PKC) may play a role as well, but its 
significance has not been tested (92, 93).   
 
TPO, C-mpl and the Hematopoietic Stem Cell 
There is a growing body of research demonstrating that TPO and c-mpl play some 
role in the stimulation, proliferation, and development of HSC.  When c-mpl was first 
identified in 1993, it was shown to be expressed not only in MK and platelets, but in 
purified CD34+ cells from BM and blood monocytes by RT-PCR (54).  However, more 
recently it was demonstrated by flow cytometry that 70% of murine HSC in BM are c-
mpl positive and that genetic elimination of c-mpl reduces the potency of HSC to 
repopulate 7-fold (94).  Dendritic cells, which develop from HSC, have also now been 
shown to express c- mpl (95).  Additionally, TPO has been reported to have a synergistic 
effect with steel factor, an early HSC growth factor, and IL-3 to promote formation of 
multilineage HSC colonies (96).  Soluble c-mpl has also been shown to act in synergy 
with steel factor to produce formation of multilineage colonies (97).  Also, TPO has been 
shown to act synergistically with granulocyte colony stimulating factor (G-CSF) to 
promote neutrophil recovery in myelosuppressed mice (98).  
Perhaps the most convincing evidence is from the study of c-mpl deficient mice.  
It has been shown that mice with a c-mpl knockout have lower numbers of not only MK 
progenitors and MK, but erythroid, granulocyte-macrophage, and multilineage precursor 
cells as well (99).  C-mpl mice now serve as a model system to study the human disease 
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congenital amegakaryocytic thrombocytopenia (CAMT).  CAMT is characterized by an 
essential thrombocytopenia which develops into a pancytopenia / aplastic anemia later in 
life.  The disease has been shown to be caused by mutations in c-mpl, which further 
suggests a role of TPO and its receptor in HSC survival and development (100). 
This body of evidence demonstrates that c-mpl is not conserved strictly to MK 
and is expressed on other cells at various stages of maturity in the hematopoietic lineage.  
This research also suggests that TPO can act synergistically with other cytokines to 
promote growth of granulocytes, macrophages, and erythroid progenitor cells.   
Therefore, given that OC are also of the hematopoietic lineage, it is plausible that c-mpl 
may be expressed on OC precursors and that TPO may play a direct role in 
osteoclastogenesis.     
 
The Megakaryocyte and Bone 
Evidence for a role of MK in bone formation comes from data indicating that MK 
express mRNA for, and secrete the bone matrix protein osteocalcin (39).  The expression 
of osteocalcin by BM MK and peripheral blood platelets is significant in that these are 
the only known extra-osseous cells that secrete osteocalcin (39).  In addition to 
osteocalcin, MK or platelets also secrete other matrix proteins including osteonectin, 
bone sialoprotein, and osteopontin (40, 41, 43, 44).  More recently, bone morphogenetic 
proteins -2, -4, and -6 have been immunolocalized in MK (101).  These data suggest that 
MK could, under the appropriate circumstances, contribute to bone formation by the 
secretion of these proteins.  On the other hand, MK have also been reported to stimulate 
the differentiation of OB as defined by enhanced expression of procollagen (102).   
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A limited amount of evidence also suggests a possible role for MK in OPG 
mediated bone remodeling.  In two investigations, immunohistochemical analysis showed 
that MK stained positive for an OPG specific antibody (102, 103).  Bord et al (102) also 
showed that OPG expression increased in estradiol treated MK cultures as culture 
duration increased, MK maturation also increased.  In another study, MK expression of 
OPG was documented using RT-PCR and immunolocalization techniques (104).  Based 
on immunostaining, these authors suggested that larger, more mature MK contained more 
OPG.  However, this latter study did not find demonstrable levels of OPG in human MK 
conditioned medium (CM).  While not determined experimentally, it was theorized that 
the OPG, if secreted, binds significant amounts of the MK expressed RANKL (102, 105).  
On the other hand, OPG was detected in CM from MK isolated from C57BL/6 and 
GATA-1 mice (450±62 and 242±17 pg/ml, respectively) (106).  Since MK from GATA-1 
deficient mice are arrested at an immature stage of differentiation, this data lend further 
support to the hypothesis that more mature MK contain higher quantities of OPG (107).  
Moreover, the fact that MK appear to be a source of OPG implicates a potential role for 
MK in regulating OPG levels and RANKL expression and implies that MK could be 
involved in bone resorption and therefore bone remodeling. 
Additional evidence for a role of MK in bone remodeling comes from studies of 
mice deficient in GATA-1 and NF-E2, the previously described transcription factors 
required for MK differentiation.  Mice deficient in these transcription factors have a 
phenotype characterized by increased numbers of immature MK, a concomitant drastic 
reduction of platelets, and a striking increased bone mass (108-110).  A marked 2-3-fold 
increase in trabecular bone volume and bone formation indices were observed in these 
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mice.  A 20-150-fold increase in trabecular bone volume was measured for the entire 
femoral medullary canal.  In vivo OB number and bone formation parameters were 
significantly elevated.  When wild-type or mutant OB were cultured with MK from 
GATA-1 or NF-E2 deficient mice, OB proliferation increased 3-6-fold by a mechanism 
that required cell-to-cell contact.  These observations demonstrated a novel interaction 
between MK and OB which resulted in an increased bone mass, a here-to-fore, 
unrecognized anabolic pathway in bone (110).   
 
Cytokines Involved in Megakaryopoiesis and Osteoclastogenesis 
 Many of the pleiotropic cytokines that stimulate megakarypoiesis also play some 
role in osteoclastogenesis.  As Fig. 3 depicts, these cytokines include but probably are not 
limited to IL-11, stem cell factor (SCF), leukemia inhibitory factor (LIF), IL-6, and G-
CSF (111).  IL-11, in addition to its role in many stages of MK differentiation, is known 
to stimulate macrophages (112, 113).  Further IL-11 has been shown to upregulate 
RANKL expression in cells of the OB lineage, which in turn can enhance OC formation 
(114).  Similarly, SCF, the ligand of c-kit, acts in the early stages of megakaryopoiesis 
and is also known to enhance osteoclastogenesis (115, 116).   
LIF has been documented as being involved with the differentiation of 
multipotential progenitors into MK progenitors as well as the differentiation of MK 
progenitors into immature MK (111).  LIF has been implicated in modulating OC 
differentiation by two separate mechanisms.  First, LIF appears to upregulate RANKL 
expression in cells of the OB lineage while simultaneously decreasing OPG expression 
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(117).  Additionally, LIF may upregulate c-fms expression in osteoclast precursors (118).  
Both of these effects enhance osteoclastogenesis.   
IL-6 promotes megkaryopoiesis, megakaryocyte differentiation, and raises 
platelet levels in vivo (119-121).  Like IL-11, IL-6 has been implicated in OC 
differentiation through the upregulation of RANKL by cells of the OB lineage.  In 
addition to increasing RANKL expression, OPG expression is reduced with IL-6 
stimulation, leading to enhanced osteoclastogenesis (122).  G-CSF is important for the 
normal differentiation of multipotential progenitors into MK progenitors (111).  G-CSF is 
also important in OC development.  G-CSF facilitates the development of OC progenitors 
from HSC and overexpression of G-CSF in vivo induces osteopenia as a result of 
increased numbers of OC (123, 124). 
Lastly, TPO, the main MK growth factor is critical for all stages of 
megakaryopoiesis (47, 113, 125).  It is unknown whether TPO has a direct effect on 
osteoclastogenesis; however, given the wealth of data demonstrating an overlap of 
cytokines involved in both megakaryopoiesis and osteoclastogenesis, it is plausible that 
TPO could potentially directly affect osteoclastogenesis.  The purpose of this current 
research endeavor is to determine whether TPO directly affects osteoclastogenesis.    
 
Thrombopoietin and Bone 
There are only a few studies examining the role of TPO in skeletal homeostasis.  
A myelofibrotic syndrome with osteosclerosis can be induced in mice by either repeated 
injections with TPO or by infecting mice with a virus vector carrying the TPO gene (126-  
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Figure 3.  Pleiotropic cytokines involved in megakaryopoiesis and osteoclastogenesis. 
 
 
128).  The fibrotic disease was prominent in mice over expressing the factor at 9 months 
of age.  TGFβ-1 and platelet derived growth factor (PDGF), which are secreted by MK, 
were increased 2-fold and 5-fold, respectively, in the platelet-poor plasma of the TPO 
overexpressing mice as compared to controls (128).  These data suggest that the MK 
secrete increased amounts of TGFβ-1 and PDGF, which are responsible for the 
myelofibrosis and osteosclerosis.  This theory is also supported by recent work by 
Vanucchi et al (129).  These studies have shown that GATA-1 low mice and TPO 
overexpressing mice both have a myelofibrotic phenotype and increased TGFβ-1 levels 
in the extracellular fluid, therefore implicating the MK as the source of TGFβ-1 increase 
that leads to myelofibrosis (129).  Moreover, it has been shown that in mice with TGFβ-1 
deficient BM, TPO overexpression does not induce myelofibrosis (130).   
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Conversely, another study suggests that upregulation of OPG causes an 
osteosclerotic phenotype in TPO overexpressing mice by inhibiting osteoclastogenesis 
(131).  These authors theorized that the OPG was derived from the stromal cells.  In light 
of the data showing that OPG is secreted by MK and the reports of OPG being expressed 
or localized in MK, it is possible that MK could also be directly contributing to the OPG 
levels described in the TPO overexpressing mice (102-104).  Alternatively, like MK, 
other non-mesenchymal/stromal cells could also be contributing to the increased OPG 
levels. 
A recent study by Kakumitsu et al (132) also supports a role of OPG and TGFβ-1 
in the myelofibrotic, osteosclerotic phenotype in TPO overexpressing mice.  Using 
transgenic mice that continuously secrete TPO, this group demonstrated that the mice 
develop anemia, myelofibrosis, and osteosclerosis.  These mice had elevated numbers of 
MK, with an accompanying significant increase in the plasma levels of TGFβ-1 and 
OPG.  Interestingly, these mice also demonstrated an increased number of peripheral 
neutrophils in the blood, granulocytic immature cells, myeloid precursor cells, and 
erythroid precursor cells in the BM despite the myelofibrosis and subsequent anemia, 
further implicating a role for TPO in HSC survival and development.     
Another investigation suggested that the mechanism of the increased bone 
phenotype in TPO overexpressing mice was due to the inhibition of osteoclastogenesis 
(133).  In this study the effect of TPO on OC formation in vitro was examined.  The data 
showed that TPO reduced OC number in a dose-dependent manner.  However like the 
other previously mentioned studies, Wakikawa et al (133) reported that MK number and 
maturation increased in these experiments. 
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The confounding factor in all of these studies is the presence of MK.  Because 
TPO stimulates MK proliferation, adding TPO to BM co-culture systems that contain 
MK and/or MK progenitors, will by definition increase the number of MK in the culture 
compared to cultures containing no TPO.  Therefore, it is possible that the increased 
number of MK is responsible for the inhibition of OC formation seen by Wakikawa et al 
(133).  Indeed, recent studies have shown that MK cultured in the absence of TPO, inhibit 
OC formation in a dose-dependent manner (106).  In addition, MK CM (TPO-free) also 
inhibited OC formation in a dose-dependent manner (106).  Therefore it appears that TPO 
may play an indirect role in bone resorption by inhibiting OC formation by increasing 
MK.    
The role of TPO in bone homeostasis remains unclear due to the presence of MK 
in these prior studies.  The purpose of our research is to better characterize the 
relationship between TPO and OC and to determine if a direct relationship exists 
independently of MK.   
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Hypothesis and Aims 
From our review and analysis of the literature, there were three aspects which highlight 
the purpose of this research.  First, it was evident that c-mpl was not only expressed in 
MK, but in other cells derived from HSC such as dendritic cells.  Furthermore, it was 
demonstrated that TPO acts synergistically with other cytokines to stimulate growth of 
erythroid, granulocyte, and macrophage progenitors and therefore was not solely 
restricted  to cells of the MK lineage.  Second, it was becoming increasingly evident that 
several cytokines stimulate both megakaryopoiesis and osteoclastogenesis such as IL-11 
and G-CSF.  Third and last, there was substantial evidence supporting an indirect role for 
TPO in inhibition of osteoclastogenesis by promoting megakaryopoiesis; however, a 
more precise relationship between TPO and OC without the confounding effects of MK 
has yet to be studied or reported in the literature.  To this end, we hypothesized that OC 
precursors express c-mpl, the TPO receptor, and that TPO directly affects OC 
formation in vitro.  The following specific aims test this hypothesis: 
 
Specific Aim I.     To verify the ability of MK to decrease OC formation in vitro.  OC 
progenitors were cultured in the presence of M-CSF and RANKL to promote 
osteoclastogenesis.  Once OC were formed, cells were fixed, stained for tartrate resistant 
acid phosphatase (TRAP), and TRAP+ multinucleated (>3) cells were counted.  This 
control population was then compared to a population of OC progenitors that had been 
exposed to MK or MK CM to determine if a significant decrease in OC number had 
occurred.   
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Specific Aim II.    To test the effects of TPO to on OC formation in vitro in the 
absence of MK and/or MK precursors.  OC progenitors that did not contain MK or 
MK precursors (Pax5-/- spleen cell line [SCL] and BMM) were cultured in the presence 
of M-CSF and RANKL with or without TPO.  Once OC were formed, cells were fixed, 
stained for TRAP, and TRAP+ multinucleated (>3) cells were counted. 
 
Specific Aim III.   To characterize the expression of c-mpl in OC progenitors.   C-
mpl expression in OC progenitors was examined using Real-Time PCR (RT-PCR).  RNA 
was isolated from MK and OC progenitor cells.  The RNA was converted to cDNA, and 
subsequently purified prior to PCR amplification.  MK served as a positive control for 
expression of c-mpl.  C57BL/6 BMM, RAW264.7, and Pax5-/-SCL were the OC 
progenitor cells that were utilized.     
 
Specific Aim IV.  To begin dissecting the signal transduction pathway that occurs 
when OC are stimulated with TPO.  In Aim IV, we tested the hypothesis that TPO 
induces receptor dimerization, tyrosine phosphorylation, and a series of signaling events 
that results in the enhancement of OC development.  Primary BMM derived from 6-8 
week-old C57BL/6 mice or the Pax5-/- SCL OC progenitors were used.  Cells were 
serum starved overnight and then stimulated with 100 ng/ml of recombinant murine TPO 
for 0, 1, 3, 5, 10, or 30 minutes.  As a positive control, primary MK derived from the fetal 
livers of E13.5-15.5 C57BL/6 mice or mpl-transfected, TPO dependent Ba/F3 cells were 
serum starved and then stimulated with TPO for 0 or 10 minutes.  Lysates were collected 
and immunoblotted with antiphosphotyrosine antibodies (αP-Tyr). 
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Materials and Methods 
 
1**. Preparation of BM Cells: Tibiae and femurs were dissected from 6-10 week old 
C57BL/6 mice, the epiphyses removed, and the marrow flushed with 2-3 mls of ice cold 
α-MEM with 10% FCS (vol/vol) using a 27 gauge needle and syringe. A single cell 
suspension was prepared and the cells were washed 2x prior to use. 
 
2. Preparation of Whole Spleen Cells:  Spleens from adult C57BL/6 mice were 
dissected out and placed in a sterile culture dish containing PBS with 2% FCS (vol/vol).  
The fibrous capsule was then broken, releasing spleen cells which were made into single 
cell suspensions.  Fibrous tissue was removed and cells were washed 2x.  
  
3. Preparation of Fetal Liver cells:  Although fetal livers and adult spleens are good 
sources of MK, substantially more MK (at least 5x, data not shown) are obtained from 
fetal liver preparations (MA. Kacena).  Fetuses were dissected from pregnant mice at 
E13.5-15.5.  The livers were removed and single cell suspensions made by forcing cells 
thru sequentially smaller gauge needles (18G, 20G, 23G).  Cells were washed 2x with 
DMEM + 10% FCS and then seeded (5 fetal livers/100 mm dish) in 100 ml culture 
dishes, in DMEM + 10% FCS + 1% murine TPO (128).  After 3-5 days, when the cells 
become confluent, MK were obtained by separating them from the lymphocytes and 
other cells using a one-step albumin gradient to obtain a 95% pure MK population (134). 
The bottom layer was 3% albumin in PBS (Bovine Albumin, protease free, fatty acid 
poor, Serologicals Proteins Inc.), the middle layer was 1.5% albumin in PBS, and the top 
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layer contained the cells to be separated. All of the cells sedimented through the layers at 
1g for approximately 40 minutes at room temperature. The MK fraction was collected 
from the bottom of the vessel.  The non-MK (NM) derived fraction was composed of the 
remaining cells.   
 
4. Preparation of MK CM:  MK were isolated as described above, washed 2x, and 
seeded into 6-well plates at a concentration of 1x106 cells/ml.  They were cultured in α-
MEM supplemented with 10% FCS.  After 72 hrs, the CM was centrifuged, sterile 
filtered, aliquoted, and stored at -20ºC. 
 
5*.  Preparation of Bone Marrow Macrophages (BMM):  BM cells were prepared as 
above.  5x107 cells/ml were seeded into a 100 mm tissue culture dishes, in α-MEM 
supplemented with 10% FCS and 20 ng/ml of M-CSF (R&D Systems).  After 3 days in 
culture, cells were lifted with trypsin, and were adjusted to a concentration of 100,000 
cells/ml for OC generation as described below.  
 
6*.  Preparation of Pax5-/- SCL:  Pax5-/- spleen cells (2.5x106 cells/ml) were prepared 
as above, and were cultured in 100 mm tissue culture plates in α-MEM with 10% FCS 
for 10 days. The nonadherent cells were washed away and the adherent cells were 
released from the dish by treatment with EDTA/trypsin (0.032%).  Pax5-/- SCL is a 
purified monocyte/macrophage OC progenitor cell line developed by our laboratory, 
which does not contain MK, lymphocytes, or other accessory cells.  The Pax5-/-SCL was 
chosen because OC develop from these cells in ~3 days, when cultured with M-CSF and 
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RANKL to induce OC formation.  The Pax5-/- SCL was transferred and fed weekly 
(135). 
 
7*. In Vitro OC-like Cell Formation Models:  OC-like cells were generated by two 
previously described methods (136, 137).  First, co-cultures containing 2x106 spleen cells 
or BM cells/ml and 20,000 primary calvarial OB/ml were grown in α-MEM 
supplemented with 10% FCS and 10-8 M 1,25(OH)2D3.  The media was changed every 
other day for 6-8 days.  Second, 2x106 spleen cells or BM cells/ml or 100,000 Pax5-/- 
SCL or BMM were cultured in α-MEM supplemented with 10% FCS and 30 ng/ml of M-
CSF (R&D Systems) and 50 ng/ml RANKL (R&D Systems).  Media was changed every 
third day for 6-12 days (until OC formed).  In each of the above models, once OC 
formed, the cells were fixed with 2.5% glutaraldehyde in phosphate buffered saline for 30 
minutes at room temperature, stained for TRAP using a kit from Sigma, and TRAP+, 
multinucleated (>3) OC cells were counted.  TPO was titrated (0-1000ng/ml) into 
cultures.   
 
8*. RNA Extraction and RT-PCR:    Cells were washed 2x with PBS.  RNA was 
isolated from the cells using a NucleoSpin II RNA Purification kit (BD Biosciences) 
incorporating an on-column DNase treatment to remove contaminating genomic DNA.  
For RT-PCR, cDNA was prepared from 5μg of total RNA using Sprint PowerScript 
Reverse Transcriptase (BD Biosciences) and oligo(dT)12-18 primers.  The cDNA was 
purified using an Amicon YM30 filter device (Millipore).  Quantitative RT-PCR was 
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performed on a Cepheid Smart Cycler using Platinum Taq polymerase (Invitrogen) and 
Sybr Green I (Molecular Probes) incorporation.   
The quantitative comparison between samples was calculated using comparative 
CT.  The data was normalized by subtracting the difference of the threshold cycles (CT) 
between the gene of interest (c-mpl) and the CT of the housekeeping gene glyceraldehyde 
3-phosphate dehydrogenase (GAPDH).  This value is defined as the ΔCT.  To compare 
the relative expression of c-mpl in two types of cells (e.g. primary C57BL/6 MK vs. 
primary C57BL/6 BMM) the ΔΔCT must be calculated.  ΔΔCT for this example is the 
absolute value of the difference between the ΔCT for the MK and the BMM or |ΔCT MK - 
ΔCT BMM|.  The relative difference (fold increase or decrease) in expression is 
calculated as 2ΔΔCT.   The following were the sequences used for the c-mpl:  
forward primer: 5’ TCACCTTGGTGACTGCTCTG  
reverse primer: 5’ GGACTTAGGGCTGCAGTGTC  
The following were the sequences used for GAPDH:  
forward primer: 5’ CGTGGGGCTGCCCAGAACAT  
reverse primer: 5’ TCTCCAGGCGGCACGTCAGA 
 
9*.  Cell Stimulation and Lysis:  Seventy-five percent confluent cultures of C57BL/6 
BMM and Pax5-/- SCL, C57BL/6 MK, or Ba/F3 cells were placed in reduced serum 
media (0.5%) for 16-18 hours.  The cells were stimulated with human recombinant TPO 
(100 ng/ml) for 0, 1, 3, 5, 10, and 30 minutes.  At the end of the incubation period, cells 
were immediately rinsed with two changes of ice-cold PBS containing inhibitors (100 
μM PMSF, 10 μg/ml leupeptin, 2 μg/ml aprotinin, 1 μg/ml pepstatin, 200 μM sodium 
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orthovanadate).  After aspirating the PBS/inhibitors, the cells were placed (adherent cells 
were scraped) in the appropriate volume of lysis buffer containing 20 mM Tris, pH7.2, 
150 mM NaCl, 1.0% Triton X-100, 1.0% sodium deoxycholate, 0.1% SDS, and 5.0 mM 
EDTA.  The following protease and phosphatase inhibitors were also added to the lysis 
buffer:  1 mM PMSF, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 1 μg/ml pepstatin, 1 mM 
sodium orthovanadate, and 50 mM sodium fluoride.  Lysates were centrifuged for 15 
minutes a 12,000xg at 4°C and supernatants were collected.  Protein concentration was 
determined using a Micro BCA protein assay kit with BSA as the standard.  Each sample 
used for Western blotting was adjusted to contain equivalent amounts of protein.   
 
10**.  Western Blotting:  Cell lysates (200-500 μg) were pre-cleaned with Protein A-
Sepharose for 1 hour at 4°C.  Protein A-Sepharose was removed and cell supernatants 
were incubated in the appropriate antibody (e.g. αP-Tyr)  for 2-16 hours at 4°C.  The 
antigen-antibody complexes were recovered during a 30-60 minute incubation using 
rabbit anti-mouse immunoglobulin and protein A-Sepharose or protein A-Sepharose 
alone.  The immune complexes were washed 3-5 times with lysis buffer and the 
immunoprecipitated proteins were eluted into SDS-PAGE sample buffer (3% SDS, 
60mM Tris, pH 6.9, 2 mM EDTA, 4% glycerol) by heating the samples to 100°C for 5 
minutes. 
 
11*. Statistical Analysis:  Statistical significance from controls was determined using 
student’s t –test.  For all figures, the data are presented as an average with the error bar 
representing the standard deviation.   
  




*  I conducted these experiments and generated data from them. 
** I was trained in these procedures, but did not perform them regularly or generate data    
from them.   
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    Results 
 
MK Inhibit OC Development In Vitro 
Spleen cells (2x106 cells/ml) from C57BL/6 mice, as a source of OC precursors, 
were cultured with M-CSF (30 ng/ml) and RANKL (50 ng/ml) to induce OC formation.  
It should be noted that similar data was obtained regardless of whether OC were 
generated using spleen or BM cells as the source of OC precursors.  Therefore, to avoid 
redundancy we show only the data using spleen cells.  C57BL/6 or GATA-1 deficient 
MK were titrated into the culture wells and OC were identified as those cells that were 
TRAP+ with >3 nuclei.  Spleen cells (2x106 cells/ml) from C57BL/6 mice as a source of 
OC precursors, demonstrated up to a 15-fold reduction in OC number when 5,000 or 
10,000 MK were added to the spleen cell cultures, p < 0.001 (Fig. 4).  This data also 
shows that the MK from GATA-1 deficient mice are also able to inhibit OC formation in 
vitro, but that the inhibition was significantly less pronounced, p < 0.04,  than that seen 
with equivalent numbers of C57BL/6 MK.   
To rule out the possibility that the MK-induced OC inhibition was non-specific, 
spleen cells treated with M-CSF and RANKL were cultured with MK, the non-MK (NM) 
derived fraction (see preparation of fetal liver cells in Materials and Methods), or 
C57BL/6 thymocytes as an unrelated cell type.  A dose-dependent inhibition of OC 
formation was again observed (Fig. 5).  In contrast, at all concentrations tested, neither 
thymocytes nor the non-MK cell fraction inhibited OC development.  These data suggest 
that the inhibition of OC formation was MK specific.  Next, we confirmed that MK were 
also able to inhibit OC formation in the co-culture model system.  In these experiments 
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C57BL/6 spleen cells (2x106 cells/ml) were cultured with freshly prepared C57BL/6 
calvarial OB (20,000 cells/ml).  Cultures were treated with 10-8 M 1,25(OH)2D3 to 
enhance OC differentiation.  C57BL/6 MK inhibited OC formation in a cell-number 
dependent manner (data not shown). 
Furthermore, inhibition of OC formation was also observed in the Pax5-/- SCL 
model system.  When just 2500 C57BL/6 MK (5%) were added to the SCL cultures, 
there was a statistically significant, greater than 8-fold reduction in OC number recorded 
when compared to control, p < 0.001.  However, adding higher numbers of MK did not 
further reduce OC number (Fig. 6).  
Next, we generated MK CM and tested the ability of this CM to inhibit OC 
formation.  Here we cultured 1x106 C57BL/6 MK/ml, 1x106 GATA-1 deficient MK/ml 
or 5x105 MEG-01 (a megakaryoblastic cell line) cells/ml for 3 days (pretested and shown 
to have highest activity at day 3, data not shown) before collection. As Fig. 7 depicts, 
C57BL/6 MK, GATA-1 deficient MK, and MEG-01 CM significantly inhibited OC 
formation in a dose-dependent manner, p < 0.001.  For C57BL/6 MK CM the ED50 was 
approximately equal to 2% (vol:vol).  These data indicate that a soluble factor(s) secreted 
by either primary MK or a MK cell line was capable of inhibiting OC differentiation. 
The data presented above demonstrate that MK cultured in the absence of TPO, 
inhibit OC formation in a dose-dependent manner.  Further, TPO-free MK CM also 
inhibited OC formation in a dose-dependent manner.  This data, performed in our 
laboratory, serves as the preliminary results from which the following TPO experiments 
were designed.    
  




Figure 5.  Dose-dependent inhibition of 
OC by C57BL/6 MK after 9 days in 
culture.  MK, non-MK (NM), or 
thymocytes were titrated into spleen cell 
cultures and were stimulated to induce 
OC formation.  MK inhibited OC in a 
dose-dependent manner (* = p < 0.008).  
NM and thymocytes did not inhibit OC 
development at any of the concentrations 
tested.  Triplicate cultures were tested 
within individual experiments and 






Figure 4.  Inhibition of OC formation by 
MK after 9 days in culture.  Both 
C57BL/6 and GATA-1 deficient MK 
markedly inhibited OC formation in vitro 
(up to 15-fold reduction, * = p < 0.001), 
although inhibition was reduced in 
cultures containing GATA-1 deficient 
MK (** = p < 0.04).  Triplicate cultures 
were tested within individual 
experiments and experiments were 
repeated 3 times. 
 
 
Figure 6.  A greater than 8-fold reduction 
in OC formation by C57BL/6 MK (BSA-
gradient separated on day 4) was seen 
when the Pax5-/-SCL was used as a 
source of OC precursors (* = p < 0.001).  
Triplicate cultures were tested within 
individual experiments and experiments 
were repeated 3 times 
 
Figure 7.  CM concentration-dependent 
inhibition of OC development (4 days in 
culture) in Pax5-/-SCL culture model by 
C57BL/6 MK CM, GATA-1 deficient MK 
CM, and MEG-01 CM (* = p < 0.001).  
Triplicate cultures were tested within 
individual experiments and experiments 
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TPO Enhances OC Formation in Vitro in MK-Free Cultures 
OC generated from Pax5-/- SCL cultured in the absence of MK demonstrated an 
increase in cell number by 50-70% when stimulated with TPO, p < 0.04 (Fig. 7).   
Recombinant human TPO was titrated into the OC-like cell formation models at day 0.  
As shown in Fig. 8, with just 1 ng/ml of human recombinant TPO, OC number was 70% 
higher than in cultures without TPO stimulation.  Similarly, OC generated from C57BL/6 
BMM in the absence of MK were increased in a dose-dependent manner when cultured 
with TPO.  A six-fold increase in OC number was observed when these cells were 
cultured with 100 ng/ml of TPO, p < 0.01 (Fig. 9).   
This data clearly demonstrates that TPO itself enhances OC formation in vitro.  
However, if OC generating systems are used which contain MK and/or MK progenitors, 
the effects of the MK inhibiting OC formation appears to outweigh the effects of TPO 
enhancing OC formation, resulting in a net inhibition of OC formation. 
 
C-mpl Expression in OC Progenitors 
To determine whether OC progenitors express c-mpl, RT- PCR analysis was 
completed.  As described in the Materials and Methods section, the comparative CT 
method was used to compare c-mpl expression in different types of cells.  GAPDH 
mRNA served as an internal control for the c-mpl mRNA.  For each cell type used, 
mRNA was extracted separately from 3 different cultures of cells, and the RT-PCR was 
done in duplicate (the RAW264.7 OC progenitor cell line mRNA is based on only one 
mRNA culture).  All data are reported as the normalized minimum threshold cycle (ΔCT) 
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or the PCR amplification cycle at which the reporter dye fluorescence crossed the 










Figure 8.  Stimulation of Pax5-/-SCL 
OC precursors in the absence of MK 
cells with TPO (1-1000 ng/ml) 
enhances OC formation by 50-75%  
(* = p < 0.04). Duplicate cultures were 
tested within individual experiments 
and experiments were repeated 3 times 
Figure 9. Stimulation of C57BL/6 BMM in 
the absence of MK with TPO (0.1-100 
ng/ml) enhances OC formation by 6-fold 
(100ng /ml TPO, * = p < 0.01).  Duplicate 
cultures were tested within individual 
experiments and experiments were 
repeated 3 times 
As shown in Fig. 10, the ΔCT for c-mpl expression in primary C57BL/6 MK was 
25.0±1.1.  For OC progenitors, the ΔCT for c-mpl expression was 29.5±1.7 for primary 
C57BL/6 BMM, 33.08±0.04 for RAW264.7 cells, and 33.2±2.2 for Pax5-/- SCL.  
Although MK express significantly more c-mpl than do OC progenitors (2|ΔCT (MK)- ΔCT 
(BMM)| = 2|25.0-29.5| ≈ 22.6, a 22.6-fold increase), this data demonstrates that OC progenitors 
express c-mpl (<35 CT is considered legitimate c-mpl expression).  This conclusion is 
further supported by our negative control, B9 cells (B cell).  In B9 cell specimens, the 
minimum threshold level was not exceeded with 40 cycles.  This demonstrates the 
specificity of c-mpl expression.  Therefore, this expression data, in combination with the 
functional data that shows that TPO enhances OC formation in vitro, implies that TPO is 
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interacting with its receptor, c-mpl, on OC progenitors, and that this interaction begins a 











Figure 10.  Expression by RT-PCR of c-mpl  
in C57BL/6 MK, C57BL/6 BMM, RAW264.7, 
and Pax5-/-SCL.  All OC progenitor cells  
tested express c-mpl, albeit at lower 
levels than primary MK.  The data represent  
the average  ΔCT from duplicate testing of  
three sets of mRNA (only one set of  
RAW264.7 mRNA was analyzed).                      
 
TPO Induces Tyrosine Phosphorylation of Specific Cellular Proteins in OC 
Progenitors 
 In MK and platelets, signal transduction by TPO has been shown to involve 
tyrosine phosphorylation of several specific cellular proteins such as: JAK2, TYK2, 
STAT3, STAT5, mpl, Shc, vav and SHIP.  As shown in Fig. 11, TPO treatment of 
C57BL/6 BMM induced tyrosine phosphorylation of proteins with the following apparent 
mol wt:  ~105-115, ~95, ~52, and ~46 kD.  The majority of the proteins appeared to be 
rapidly tyrosine phosphorylated within 1 minute after TPO stimulation.  Phosphorylation 
of the proteins reached maximal levels within 3-5 minutes after stimulation and 
significantly diminished by 30 minutes.  While immunoprecipitation of the specific 
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cellular proteins has yet to be completed, these molecular weights are consistent with 
signaling molecules known to by tyrosine phosphorylated when MK are stimulated with 
TPO.  Whether these same signaling molecules are tyrosine phosphorylated when OC 
progenitors are stimulated with TPO is the subject of future research; however, this data 
demonstrates a signaling cascade in OC progenitors when stimulated with TPO providing 















              




Figure 11.  TPO induces tyrosine phosphorylation in 
C57BL/6 BMM.  BMM were treated with vehicle alone (0’) 
or TPO (100 ng/ml) for the various time periods indicated.  
Equal amounts of protein solubilized in lysis buffer (25 
μg/time point) were separated on 7.5% SDS-PAGE, 
transferred to nitrocellulose and probed with 
antiphosphotyrosine antibodies.  Bound antibody was 
detected in the ECL reaction.  The arrows on the right-hand 
side indicate proteins that become tyrosine phosphorylated in 
response to TPO.    
 




















In the last decade, a new paradigm has emerged in which MK have been shown to 
play an important role in skeletal homeostasis.  In brief, data demonstrate that MK may 
act as an anabolic stimulator of bone formation by expressing/secreting bone related 
proteins, or by directly enhancing OB proliferation and differentiation (39, 40, 41, 43, 44, 
101, 102, 110, 138).  Simultaneously, MK express and/or secrete several factors that are 
known to be involved in osteoclastogenesis (37, 102, 103, 104, 105, 139-143).  And, 
recent studies demonstrate that MK inhibit OC formation in vitro (106).   The net result is 
that increases in MK can lead to increases in bone volume (110, 144). 
One in vivo example of increases in MK leading to an increase in bone is TPO 
overexpressing mice.  Mice overexpressing TPO, the main MK growth factor, have an 
approximate 4-fold increase in MK number and develop myelofibrosis with 
osteosclerosis (126-128).  These mice have significantly elevated levels of TGFβ-1, 
PDGF, and OPG, all of which are known to be secreted by MK (106, 128, 131, 132, 143).  
It was hypothesized that these elevated levels were responsible for the myelofibrosis and 
osteosclerosis seen in TPO overexpressing mice.   
To further dissect this hypothesis, Chagraoui and colleagues (130, 131) performed 
several elegant experiments.  First they showed that when irradiated wild-type recipient 
mice were adoptively transferred with TGFβ-1-/- HSC that were infected with a 
retrovirus encoding murine TPO protein, TPO overexpression did not induce the 
myelofibrosis or osteosclerosis.  However, when wild-type TPO-overexpressing HSC 
were adoptively transferred, myelofibrosis and osteosclerosis was seen within 16-weeks 
(130).  Next, they performed mix and match adoptive transfer experiments with OPG.  
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They demonstrated that all mice had elevated TGFβ-1 levels and that all mice developed 
myelofibrosis, suggesting that TGFβ-1 and not OPG is critical for myelofibrosis to occur.  
Next, they demonstrated that when wild-type recipient mice were adoptively transferred 
with either wild-type or OPG-/- HSC that were infected with a retrovirus encoding 
murine TPO protein, that serum OPG levels were elevated and osteosclerosis developed.  
Interestingly, in OPG-/- recipient mice, an osteoporotic bone phenotype was observed 
(131).  This data suggests that OPG secreted by the BM stromal cells and OB in the wild-
type recipient mice is responsible for the osteosclerosis seen in TPO overexpression.           
In vitro studies by Wakikawa et al (133) also suggested that the osteosclerosis 
seen in TPO overexpressing was due to inhibition of osteoclastogenesis.   Their 
experimental design utilized a co-culture model with BM cells and stromal cells which 
inevitably contained MK and MK precursors.  Their results demonstrated TPO mediated 
inhibition of osteoclastogenesis in a dose-dependent manner.  However, Wakikawa et al 
(133) speculated the inhibitory effect of TPO on osteoclastogenesis in their co-culture 
system to be due to increased thrombopoiesis and production of MK cytokines, namely 
TGFβ-1 and PDGF.  They found that antibodies to TGFβ-1 and PDGF, when introduced 
into their model system, antagonized TPO induced inhibition of osteoclastogenesis. 
Thus, it remains unclear if TPO has a direct role in osteoclastogenesis, 
independent of MK.  To elucidate whether TPO has a direct effect on osteoclastogenesis, 
we did the following.  First, we examined the relationship between MK and MK CM and 
osteoclastogenesis.   It is evident from our data that MK inhibit OC formation in vitro.   
Spleen cells from C57BL/6 mice as a source of OC precursors demonstrated up to a 15-
fold reduction in OC number when 5,000 or 10,000 MK were added to the cell cultures 
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(Fig. 4).  Furthermore, inhibition of OC formation was also observed in the Pax5-/- SCL 
model system (Fig. 6).  Additionally, MK CM was shown to inhibit OC formation in a 
dose-dependent manner, suggesting that a soluble factor released by MK mediates OC 
formation inhibition (Fig. 7).   
Next, we studied the relationship between TPO and OC, independent of MK.  Our 
results clearly indicate that TPO exerts a direct effect on OC formation in vitro.  
Experiments in which OC were generated in the absence of MK (Pax5-/- SCL) 
demonstrated an increase in cell number by 50-70% when stimulated with TPO (Fig. 8).  
Also, up to a six-fold increase in OC number was observed after culturing C57BL/6 
BMM cells (no MK) with TPO (Fig. 9).  Interestingly, the response of C57BL/6 BMM 
cells to TPO was greater than that of the Pax5-/- SCL cells.  This data suggests that 
primary cells such as C57BL/6 BMM are more responsive to TPO stimulation than cells 
lines such as Pax5-/- SCL.  Moreover, since primary cells more closely model 
physiological response, these results further substantiate a direct role of TPO in OC 
formation.  The argument can be made that primary cells inevitably contain some degree 
of contaminating cells and that the results could be spurious.  However, all non-adherent 
cell were removed from cultures, so contaminating cells were adherent.  Furthermore, as 
cells were induced to become OC, and since only OC were assessed in this assay by 
TRAP staining, only BMM or other OC precursors were responding to TPO stimulation. 
It is evident from this data that the presence of MK or MK precursors would 
confound any attempt to elucidate a possible direct effect between TPO and 
osteoclastogenesis.  Wakikawa et al (133) observed that TPO inhibited in vitro 
osteoclastogenesis in a dose-dependent manner.  However, their co-culture model 
  
                                                                                                                                            40                         
 
 
contained MK and MK precursors.  We confirmed the dose-dependent osteoclastogenesis 
that Wakikawa et al (133) observed by introducing increasing numbers of MK into OC 
progenitor cell cultures (Fig. 5).  This suggests that Wakikawa et al (133) observed an 
indirect inhibitory effect of TPO on osteoclastogenesis due to increased 
megakaryopoiesis.     
Since the MK mediated inhibition of OC formation dominates the direct effect of 
promoting osteoclastogenesis by TPO, the implications of this direct relationship between 
TPO and OC progenitors remains unclear.  As detailed in the literature review, at least 
70% of HSC are c-mpl positive, and mature, hematopoietic non MK cells such as 
dendritic cells express the TPO receptor (94, 95).  Moreover, there is a growing body of 
research that suggests synergistic relationships between TPO and other growth cytokines 
such as G-CSF and IL-3 are essential to stem cell survival and proliferation (96, 98).  
Carver-Moore et al (99) have shown that mice with a c-mpl knockout have lower 
numbers of not only MK progenitors and MKs, but erythroid, granulocyte-macrophage, 
and multilineage precursor cells as well.  It is well established that OC are hematopoietic 
in origin.  Moreover, our data demonstrate that OC progenitors express c-mpl, albeit at 
low levels when compared to MK (Fig. 10).  Specifically, we found that the level of 
expression of c-mpl on OC progenitors is approximately 22.6-fold less than that found in 
MK.  This suggests that MK most likely bind the majority of TPO, and hence cause a net 
inhibition of osteoclastogenesis when stimulated with TPO, an indirect effect.  However, 
our data suggests that there is also a concomitant, direct, TPO-mediated signal to OC 
progenitors that promotes osteoclastogenesis.  Given the previously described research 
pointing to a crucial role for c-mpl in stem cell survival for multi-lineages of 
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hematopoietic cells, the direct stimulation of OC formation by TPO may be necessary for 
the survival and proliferation of this specific HSC population that produces OC.   
Our preliminary data suggests not only that c-mpl is expressed in OC progenitors, 
but more importantly, it is functional.  We observed rapid onset of tyrosine 
phosphorylation by Western blotting with 1 min with maximal activity at 3-5 min, 
tapering off by 30 minutes (Fig. 11).  Drachman et al (145) demonstrated that TPO 
binding to c-mpl induces tyrosine phosphorylation evident within 1 minute, generally 
peaking between 5-10 minutes, and decreasing by 60 minutes.  In their experiments, 
BaF3 cells expressing the c-mpl receptor had a dramatic increase in tyrosine 
phosphorylation in response to TPO.  The most prominent phosphotyrosine proteins 
migrated at 52 kD, 95 kD, with several bands between 115 and 125 kD, and 140 kD; less 
intense bands were seen at 45, 65-75, and 110 kD.  Our results of tyrosine 
phosphorylation occurring at ~105-115, ~95, ~52, and ~46 kD show a great deal of 
overlap.  Drachman et al (145) identified through immunoprecipitation, phosphorylated 
Shc at 52 kD and c-mpl dimer at 95 kD doublet as well as JAK2 at 125 kD.  Although 
immunoprecipitation assays are needed to identify the proteins being phosphorylated in 
our study, we did observe tyrosine phosphorylation at 52 kD and 95 kD suggesting that 
most likely, TPO/c-mpl signaling is well conserved among cell types.  But it is plausible 
that other proteins could migrate at these weights.  More importantly, this data clearly 
demonstrates that the c-mpl receptor on OC precursors is functional and that TPO 
stimulation initiates a time-dependent tyrosine phosphorylation cascade in OC precursors, 
a cell signaling event.   This further supports a direct role for TPO in osteoclastogenesis.     
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We have demonstrated that TPO as well as MK both have direct and opposing 
effects on OC formation.  We propose the following model (Fig. 12):  TPO is secreted by 
cells of the OB lineage.  Secreted TPO can bind to either cells of the MK lineage or cells 
of the OC lineage.  When TPO binds to cells of the MK lineage, MK proliferation and 
differentiation occurs.  Increases in MK number result in increases in OB number by a 
direct cell-to-cell mechanism.  Increases in MK number also results in an increase in the 
secretion of soluble mediator(s) that inhibit OC formation.  Simultaneously, TPO can 
bind c-mpl on OC progenitors, which results in an increase in OC formation and/or 
survival of HSC precursors of OC.   
In closing, our research has demonstrated a novel role for TPO as a stimulatory 
cytokine promoting osteoclastogenesis.  Moreover, we have also shown that not only is c-
mpl expressed on OC progenitor cells, but is also a functional receptor.  It has become 
evident through the literature that MK play a role in skeletal homeostasis.  However, until 
now, the role of TPO has never been studied independently of MK.  Our research is the 
first to examine the relationship between TPO and OC independently of MK.  We have 
shown that TPO plays a direct role in skeletal homeostasis by enhancing OC 
development.    Future research will be aimed at dissecting the TPO signaling pathways 
in OC, as well as functional bone resoprtion by OC stimulated with TPO.  Such research 
will provide even more insight and knowledge about the relationship between TPO and 
OC, in the hopes of continuing to reveal the mechanisms underlying skeletal homeostasis 




































Figure 12.  Model of how TPO both directly 
and indirectly regulates skeletal 
homeostasis.  TPO that is secreted by 
OB/bone marrow stromal cells (BMSC) can 
bind to either MK or OC progenitors.  C-
mpl signaling in MK progenitors results in 
enhanced MK proliferation.  MK then 
interact with OB/BMSC via direct cell-to-
cell contact which in turn upregulates 
OB/BMSC proliferation (positive feedback 
loop).  At the same time, MK secrete a 
factor that inhibits OC formation.  On the 
other hand, TPO can bind c-mpl on OC 
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